Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1695752

	registered interest
	date	13/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Card Scheme: Medical Records
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, on what date work on digitally linking Medicines and Healthcare products Regulatory Authority Yellow Card information to NHS clinical records (a) began and (b) is expected to be completed.
	tabling member constituency	Christchurch
	tabling member printed	Sir Christopher Chope
	uin	18345
	answer	answer is ministerial correction date of answer 22/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) has been working with the National Health Service to explore approaches to facilitate digital linkage of Yellow Card information to clinical records, and to potentially enable faster access to information, where considered necessary for an assessment. Any such approach would be subject to strict information governance controls and prior consultation with stakeholder groups.</p><p>In 2020, the MHRA began delivery of a substantially enhanced Yellow Card platform under the SafetyConnect programme, aligned to the recommendations in Baroness Cumberlege’s Independent Medicines and Medical Devices Safety Review. The new infrastructure is designed with the intent of enabling connectivity to other systems, to facilitate the exchange of information. During that time the MHRA has engaged with the NHS around the evolving technical options for robust and secure connectivity and enhanced user journeys. The first step in these enhancements is use of the common NHS login capability within Yellow Card, which is expected to go live in 2024.</p><p>Deeper connectivity between systems will be subject to internal and external stakeholder engagement and substantial information governance controls, with elements completed over a phased and multi-year work plan.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/03/2024 10:33:41 answering member 4044 label Biography information for Andrew Stephenson previous answer version 24322 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	242 label Biography information for Sir Christopher Chope

1682488

	registered interest
	date	16/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	X-linked Hypophosphataemia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve the (a) diagnosis and (b) treatment of X-linked hypophosphatemia.
	tabling member constituency	Wigan
	tabling member printed	Lisa Nandy
	uin	9803
	answer	answer is ministerial correction date of answer 19/01/2024 answer text <p>Genomic testing in the National Health Service in England for hypophosphataemia is currently included in the National Genomic Test Directory under the clinical indication labelled R154. X-linked hypophosphatemia is one of 200 treatable rare conditions being included in the Generation Study, a landmark research study which will sequence the whole genomes of 100,000 newborn babies being led by Genomics England in partnership with the NHS.</p><p>The study will evaluate the utility and feasibility of using whole genome sequencing to screen newborn babies for a larger number of childhood-onset rare genetic conditions in the NHS, with a decision whether this should be rolled out now or in the future based on the relevant evidence.</p><p>National Genomics Education has also developed GeNotes, which puts innovative educational resources on genomics and rare diseases at the fingertips of healthcare professionals. GeNotes includes information on hypophosphatemia to support healthcare professionals to identify and manage forms of hypophosphatemia such as X-linked hypophosphatemia.</p><p>Burosumab is now recommended and available on the NHS for treating X-linked hypophosphataemia in children and young people who are still growing. This novel treatment addresses the underlying problem, rather than compensating for phosphate loss, so is effective in helping children to grow normally.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/01/2024 12:12:41 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4082 label Biography information for Lisa Nandy

1679697

	registered interest
	date	05/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	World Health Organization
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much from the public purse the Government spent on the UK's membership subscription to the World Health Organization in 2023.
	tabling member constituency	Solihull
	tabling member printed	Julian Knight
	uin	8018
	answer	answer is ministerial correction date of answer 15/01/2024 answer text <p>The United Kingdom and all Member States of the World Health Organization (WHO) pay an annual membership fee known as an assessed contribution. The scale of the contribution is calculated by the United Nations based mainly on the country’s GDP and the contribution is used to fund the WHO’s functions. In 2023, the UK paid £20,241,404 in assessed contributions.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/01/2024 14:13:59 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4410 label Biography information for Julian Knight

1681771

	registered interest
	date	12/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	World Health Assembly
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the cost to her Department was for officials to attend the fourth meeting of the Working Group on Amendments to the International Health Regulations in July 2023.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	9335
	answer	answer is ministerial correction date of answer 24/01/2024 answer text <p>The travel and accommodation costs for officials to attend was £980.15.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/01/2024 11:28:43 answering member 4044 label Biography information for Andrew Stephenson previous answer version 11978 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1409 label Biography information for Mr Gregory Campbell

1699131

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Whooping Cough: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps to ensure adequate supplies of pertussis vaccine in the context of the rise in instances in the Czech Republic.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	20743
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>The UK Health Security Agency (UKHSA) centrally procures and manages the United Kingdom’s supply of the pertussis vaccine, for the routine national immunisation programmes. Due to the stockpiles maintained in the UK for the national programme, there is good supply available of all pertussis-containing vaccines for the routine immunisation programmes.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/04/2024 08:47:34 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1690524

	registered interest
	date	20/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure the voluntary scheme for branded medicines pricing, access and growth represents value for money.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	14904
	answer	answer is ministerial correction date of answer 23/02/2024 answer text <p>The voluntary scheme for branded medicines pricing, access and growth (VPAG) represents a landmark deal which will enable patients to access the latest lifesaving treatments more consistently, boost the United Kingdom’s position as a global superpower in advanced healthcare, technology and clinical research, and is set to save the National Health Service £14 billion over five years, in medicines costs.</p><p> </p><p>The VPAG also introduces a new payment mechanism in which older medicines that are yet to realise price reductions, will pay a higher payment rate. Those medicines that have realised price reductions will pay a lower payment rate. This ensures that the scheme is strictly pro-innovation and pro-competition, which will enhance health outcomes for patients and deliver value for money for taxpayers. It includes an additional £400 million of investment by industry over the five years of the scheme, for the VPAG Investment Programme.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/02/2024 12:35:04 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1698079

	registered interest
	date	22/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the guidance entitled 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, published on 20 November 2023, what steps her Department is taking to apply the provisions of section 6.26 on exceptional circumstances.
	tabling member constituency	Wythenshawe and Sale East
	tabling member printed	Mike Kane
	uin	20061
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>In the vast majority of instances, payments required under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth will be affordable for companies, or can be mitigated by standard price increase processes. In exceptional circumstances only, the scheme allows companies to apply to increase their National Health Service list price, and for older medicines to reduce their top-up payment percentage, even when their wider portfolio is otherwise profitable. To qualify, a product must be demonstrably uneconomic to supply, there must be clear evidence that supply disruption would otherwise occur, and this disruption must have a negative impact on patients or the NHS. The Department already has processes and committees to consider applications for exceptional circumstances, established under previous pricing schemes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20062 question first answered 15/04/2024 08:11:01 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4316 label Biography information for Mike Kane

1698080

	registered interest
	date	22/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to section 6.26 of the guidance entitled 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, published on 20 November 2023, whether her Department has been allocated additional resources to consider exceptional circumstances.
	tabling member constituency	Wythenshawe and Sale East
	tabling member printed	Mike Kane
	uin	20062
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>In the vast majority of instances, payments required under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth will be affordable for companies, or can be mitigated by standard price increase processes. In exceptional circumstances only, the scheme allows companies to apply to increase their National Health Service list price, and for older medicines to reduce their top-up payment percentage, even when their wider portfolio is otherwise profitable. To qualify, a product must be demonstrably uneconomic to supply, there must be clear evidence that supply disruption would otherwise occur, and this disruption must have a negative impact on patients or the NHS. The Department already has processes and committees to consider applications for exceptional circumstances, established under previous pricing schemes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20061 question first answered 15/04/2024 08:11:01 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4316 label Biography information for Mike Kane

1675842

	registered interest
	date	06/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled 2024 voluntary scheme for branded medicines pricing, access and growth: summary of the heads of agreement, published on 20 November 2023, what steps her Department is taking to help ensure that people with less common conditions are not disproportionately impacted by additional rebates for older medicines.
	tabling member constituency	Lincoln
	tabling member printed	Karl McCartney
	uin	5516
	answer	answer is ministerial correction date of answer 11/12/2023 answer text <p>Commitments in the current voluntary scheme for branded medicines pricing and access around patient access and uptake for innovative medicines have had a substantial positive impact on the speed of medicines access in England, ensuring that National Health Service patients benefit from cutting-edge treatments including personalised CAR-T cancer therapies, lifechanging treatments for rare conditions, and lifesaving gene therapies. The new voluntary scheme for branded medicines pricing, access and growth agreement will continue to build on these significant achievements, for example, through the piloting of new approaches for paying for ground-breaking advanced therapy medicinal products.</p><p>We do not expect disproportional impacts on people with less common conditions resulting from these policies. Provisions in the scheme allow for companies to apply for price increases should supply of products be otherwise uneconomical. Under specific circumstances an adjusted ‘Top-up Payment Percentage’ can also be considered for other older medicines where there would otherwise be a negative impact on patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 5518 question first answered 11/12/2023 16:12:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4028 label Biography information for Karl McCartney

1675843

	registered interest
	date	06/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled 2024 voluntary scheme for branded medicines pricing, access and growth: summary of the heads of agreement, published on 20 November 2023, what assessment her Department has made of the potential impact of these policies on life science SMEs.
	tabling member constituency	Lincoln
	tabling member printed	Karl McCartney
	uin	5517
	answer	answer is ministerial correction date of answer 11/12/2023 answer text <p>The Government’s Life Sciences Vision sets out our ambition to develop a globally competitive life sciences investment ecosystem in the United Kingdom. While no assessment has been made, the 2024 voluntary scheme for branded medicines pricing, access and growth includes several policies that will benefit innovative companies and drive innovation into the United Kingdom. This includes an exemption from payment for small companies with under £6m of sales to the National Health Service and a taper for medium sized companies with between £6 million and £30 million of sales.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 11/12/2023 16:10:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4028 label Biography information for Karl McCartney